View/Open

Date

Format

Metadata

Abstract

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) appear to have comparable efficacy in delaying progression of microalbuminuria to macroalbuminuria or reversing microalbuminuria to normoalbuminuria in patients with type 2 diabetes. (SOR: C, based on 2 lower-quality RCTs with disease-oriented outcomes). Neither ACEIs nor ARBs delay the early progression of nephropathy in normotensive patients with type 1 diabetes and normoalbuminuria. (SOR: C, based on a single RCT with disease-oriented outcomes.)